Brief: Abbisko Cayman Says Fgfr4 Mutant Inhibitor- Absk012 Obtained Clinical Study Approval From U.S. FDA
08/11/2023 01:05
Nov 8 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ABBISKO CAYMAN LTD CLINICAL STUDY APPROVAL FROM U.S. FDA
Further company coverage: 2256.HK
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly